Mesoblast is developing a series of high margin, off-the-shelf adult stem cell products that are obtained from a single donor, commercially expanded and frozen, and subsequently used in potentially thousands of unrelated, or allogeneic, recipients at the time and place of need.
Mesoblast listed on the Australian Securities Exchange (ASX: MSB) in December 2004.
In December 2010, Mesoblast completed its acquisition of United States company, Angioblast Systems Inc. This strategic acquisition enabled Mesoblast to broaden its product pipeline across a wider range of clinical indications including cardiovascular, oncology, eye diseases, and diabetes, in addition to its orthopedic range of products.
Also in December 2010, Mesoblast formed a strategic alliance with global biopharmaceutical company, Cephalon Inc., (now wholly owned by Teva Pharmaceutical Industries Ltd.) to develop and commercialize its novel adult stem cell therapeutics for degenerative conditions of the cardiovascular and central nervous systems. These conditions include congestive heart failure, acute myocardial infarction, stroke and Parkinson’s disease. The alliance also extends to products for augmenting bone marrow transplantation in cancer patients. Teva is funding all late stage clinical development costs worldwide for the specific products, as well as all sales and marketing costs. Mesoblast retains all manufacturing rights and will sell finished products to Teva on a transfer price basis.
In September 2011, Mesoblast formed a strategic alliance with leading biologics manufacturer, Lonza, for clinical and long-term commercial production of Mesoblast’s allogeneic adult stem cell products. The alliance will provide Mesoblast with significant commercial advantages, including certainty of capacity to meet long-term global supply of its proprietary MPC products; a purpose-built manufacturing facility to be built by Lonza exclusively for Mesoblast and exclusive access to Lonza’s cell therapy facilities in Singapore. Other commercial benefits include reduced cost of goods (COGS), increased margins on sales price, and R&D support for enhanced second generation products.